Alpha 2.0
Login Register
» Authors » Prasert Thongcharoen

Prasert Thongcharoen

Explore the profile of Prasert Thongcharoen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 2377
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Allergy & Immunology
Top 10 Co-Authors
Sorachai Nitayaphan
Jerome H Kim
Punnee Pitisuttithum
Sanjay Gurunathan
Nelson L Michael
Mark S de Souza
Merlin L Robb
Chirasak Khamboonruang
Supachai Rerks-Ngarm
Robert M Paris
Published In
Vaccine
AIDS Res Hum Retroviruses
J Infect Dis
J Virol
J Med Assoc Thai
Affiliations
Soon will be listed here.
Recent Articles
1.
Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans
Pissani F, Schulte B, Eller M, Schultz B, Ratto-Kim S, Marovich M, et al.
J Virol . 2018 Sep; 92(23). PMID: 30209165
To date, six vaccine strategies have been evaluated in clinical trials for their efficacy at inducing protective immune responses against HIV infection. However, only the ALVAC-HIV/AIDSVAX B/E vaccine (RV144 trial)...
2.
Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand
Garg S, Thongcharoen P, Praphasiri P, Chitwarakorn A, Sathirapanya P, Fernandez S, et al.
Clin Infect Dis . 2015 Oct; 62(3):383-391. PMID: 26486702
Background: Individuals infected with human immunodeficiency virus (HIV) are at increased risk for severe influenza, yet immune responses to standard-dose intramuscular (IM) influenza vaccine are suboptimal in this population. Intradermal...
3.
IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens
Karasavvas N, Karnasuta C, Savadsuk H, Madnote S, Inthawong D, Chantakulkij S, et al.
AIDS Res Hum Retroviruses . 2015 Aug; 31(11):1178-86. PMID: 26234467
RV144 correlates of risk analysis showed that IgG antibodies to gp70V1V2 scaffolds inversely correlated with risk of HIV acquisition. We investigated IgG antibody responses in RV135 and RV132, two ALVAC-HIV...
4.
Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults
Gillard P, Chu D, Hwang S, Yang P, Thongcharoen P, Lim F, et al.
BMC Infect Dis . 2014 Mar; 14:142. PMID: 24628789
Background: The pandemic potential of avian influenza A/H5N1 should not be overlooked, and the continued development of vaccines against these highly pathogenic viruses is a public health priority. Methods: This...
5.
Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial
Kijak G, Tovanabutra S, Rerks-Ngarm S, Nitayaphan S, Eamsila C, Kunasol P, et al.
J Virol . 2013 Apr; 87(13):7265-81. PMID: 23576510
The RV144 HIV-1 vaccine trial (Thailand, 2003 to 2009), using immunogens genetically matched to the regional epidemic, demonstrated the first evidence of efficacy for an HIV-1 vaccine. Here we studied...
6.
Issues in women's participation in a phase III community HIV vaccine trial in Thailand
Kaewkungwal J, Pitisuttithum P, Rerks-Ngarm S, Nitayaphan S, Khamboonruang C, Kunasol P, et al.
AIDS Res Hum Retroviruses . 2013 Jan; 29(11):1524-34. PMID: 23343395
To assess qualities and outcomes of women participating in a large, community-based HIV vaccine trial, the present study was conducted among female participants of the RV 144 prime-boost trial in...
7.
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E
Rerks-Ngarm S, Paris R, Chunsutthiwat S, Premsri N, Namwat C, Bowonwatanuwong C, et al.
J Infect Dis . 2012 Jul; 207(8):1195-205. PMID: 22837492
Background: The Thai Phase III Trial of ALVAC-HIV and AIDSVAX B/E showed an estimated vaccine efficacy (VE) of 31% to prevent acquisition of human immunodeficiency virus (HIV). Here we evaluated...
8.
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144
Robb M, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, et al.
Lancet Infect Dis . 2012 Jun; 12(7):531-7. PMID: 22652344
Background: The Thai phase 3 HIV vaccine trial RV 144 showed modest efficacy of a vaccine against HIV acquisition. Baseline variables of age, sex, marital status, and risk did not...
9.
HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E
Paris R, Bejrachandra S, Thongcharoen P, Nitayaphan S, Pitisuttithum P, Sambor A, et al.
Vaccine . 2011 Nov; 30(5):832-6. PMID: 22085554
Immune responses to vaccines may be influenced or associated with allelic variants of host genes such as those encoding human leucocyte antigens (HLA). We have molecularly determined the HLA class...
10.
Cross-clade immunogenicity and antigen-sparing with an AS03(A)-adjuvanted prepandemic influenza vaccine in a Thai population
Thongcharoen P, Auewarakul P, Hutagalung Y, Ong G, Gillard P, Drame M, et al.
J Med Assoc Thai . 2011 Aug; 94(8):916-26. PMID: 21863672
Objective: The present study (NCT00449670) in Asian subjects (18-60 years) evaluated the manufacturing consistency of four formulations of 3.75 mg AS03(A)-adjuvanted H5N1 influenza vaccine, in terms of post-immunization Hemagglutination Inhibition...